It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables high evolvability but their evolution has not been investigated. Here we apply multi-region exome sequencing (MSeq) to four treatment-naive dMMR GOAs. This reveals extreme intratumour heterogeneity (ITH), exceeding ITH in other cancer types >20-fold, but also long phylogenetic trunks which may explain the exquisite immunotherapy sensitivity of dMMR tumours. Subclonal driver mutations are common and parallel evolution occurs in RAS, PIK3CA, SWI/SNF-complex genes and in immune evasion regulators. MSeq data and evolution analysis of single region-data from 64 MSI GOAs show that chromosome 8 gains are early genetic events and that the hypermutator-phenotype remains active during progression. MSeq may be necessary for biomarker development in these heterogeneous cancers. Comparison with other MSeq-analysed tumour types reveals mutation rates and their timing to determine phylogenetic tree morphologies.
Tumours that are deficient in mismatch-repair genes should, in theory, have higher evolvability. Here, the authors explore this theory in gastro-oesophageal tumours.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); The Royal Marsden Hospital, Biomedical Research Centre, London, United Kingdom (GRID:grid.424926.f) (ISNI:0000 0004 0417 0461)
2 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
3 The Institute of Cancer Research, Bioinformatics Core, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
4 The Institute of Cancer Research, Tumour Profiling Unit, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
5 University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)
6 University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484); University Hospital Fuerth, Institute of Pathology, Fuerth, Germany (GRID:grid.411668.c) (ISNI:0000 0000 9935 6525)
7 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); The Royal Marsden Hospital, Gastrointestinal Cancer Unit, London, United Kingdom (GRID:grid.424926.f) (ISNI:0000 0004 0417 0461)